ProCE Banner Activity

Considerations When Managing HR+/HER2- Breast Cancer With CDK4/6 Inhibitors

Clinical Thought

In this commentary, expert faculty discuss best practices for integrating CDK4/6 inhibitors into care for patients with HR+/HER2- breast cancer, including adverse event management and strategies for promoting adherence.

Released: May 31, 2022

Expiration: May 30, 2023

No longer available for credit.



Julia A. LaBarbera

Julia A. LaBarbera, MSN, RN, AGACNP-BC

Breast Oncology
UCLA Medical Center
Los Angeles, California


This activity is supported by an educational grant from Lilly.



Target Audience

NPs and PAs in oncology


Julia LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: Biotheranostics, MJH Life Sciences.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.


Clinical Thought


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.